1. Title

Response of serum fibroblast growth factor 21 (FGF21) levels to exercise program

2. Researchers
2a. Identification

<table>
<thead>
<tr>
<th>Name</th>
<th>Institutional position</th>
<th>Research position</th>
<th>Telephone (ext.)</th>
<th>E-mail</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Cuevas-Ramos</td>
<td>Consultant, Clinical Researcher</td>
<td>Principal researcher</td>
<td>54870900 (2407)</td>
<td><a href="mailto:shiverqks@hotmail.com">shiverqks@hotmail.com</a></td>
</tr>
<tr>
<td>Paloma Almeda-Valdés</td>
<td>Consultant, Clinical Researcher</td>
<td>Coinvestigator</td>
<td>54870900 (2407)</td>
<td><a href="mailto:palomaalmeda@yahoo.com">palomaalmeda@yahoo.com</a></td>
</tr>
<tr>
<td>Clara E. Meza-Arana</td>
<td>Nutritionist</td>
<td>Coinvestigator</td>
<td>54870900 (2407)</td>
<td><a href="mailto:claraelena88@hotmail.com">claraelena88@hotmail.com</a></td>
</tr>
<tr>
<td>Griselda Brito-Córdova</td>
<td>Nutritionist</td>
<td>Coinvestigator</td>
<td>54870900 (2407)</td>
<td><a href="mailto:grisbrito@hotmail.com">grisbrito@hotmail.com</a></td>
</tr>
<tr>
<td>Fco. J Gómez-Pérez</td>
<td>Chief, Department of Endocrinology</td>
<td>Coinvestigator</td>
<td>54870900 (2407)</td>
<td><a href="mailto:fcogomezpz@aol.com">fcogomezpz@aol.com</a></td>
</tr>
<tr>
<td>Jorge Ossequera-Moguel</td>
<td>Chief, Department of Cardiology</td>
<td>Coinvestigator</td>
<td>54870900 (2405)</td>
<td><a href="mailto:drosequera@intermedik.com.mx">drosequera@intermedik.com.mx</a></td>
</tr>
<tr>
<td>Carlos Aguilar-Salinas</td>
<td>Subdirector, Department of Endocrinology</td>
<td>Coinvestigator</td>
<td>54870900 (2407)</td>
<td><a href="mailto:caguilarsalinas@yahoo.com">caguilarsalinas@yahoo.com</a></td>
</tr>
</tbody>
</table>

3. Institutions participating in the study

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ), Vasco de Quiroga 15, Sección XVI, CP14000, Tlalpan, Mexico City, Mexico

4. Funding

Department of Endocrinology, INCMNSZ
Science and Technology National Council (CONACYT)

4b. Monetary income to researcher related with the study protocol

None

5. Background

Introduction

The fibroblast growth factor 21 (FGF21) is a recent described member of the FGFs family. It is particularly expressed in liver (1) and adipose tissue (2). Its main function is to increase glucose uptake in adipose tissue (3). When is overexpressed in transgenic mice, protects animals to diet induced obesity. In addition, the subcutaneous administration to mice (3) and rhesus monkeys with diabetes (4) decreased glucose and triglyceride levels. In vitro and in vivo studies have shown a significant association between FGF21 with glucose and insulin metabolism. The administration in diabetic mice also produces a significant reduction in postprandial glucose and insulin (3).

Badman et al. (5) e Inagaki et al. (6) showed that FGF21 expression in the liver of fasting mice was activated by PPAR-alfa nuclear receptor. The endogenous ligand of PPAR-alfa are fatty acids. The expression of PPAR-alfa in liver also induces higher activity of enzymes related with fatty acid oxidation and acetyl-CoA formation. The result is the increment of ketone bodies as an additional source of energy. From the liver, ketone bodies are released for future utilization in other tissues, particularly the brain. As reported Badman et al (5) and Inagaky et al (6), FGF-21 increased fatty acids oxidation and induce the metabolic process to ketone body formation. In addition, a significant increment in FGF21 transcription was induced with fasting, and it was absent in knock-out mice without PPAR-alpha. These observations, conclude the authors, link FGF21 and PPAR-alpha in one signaling pathway.

Definition of the study problem
Clinical studies in humans have shown inconsistent results regarding the role of FGF21 in metabolism. A positive and significant correlation have been reported between FGF21 and cardiovascular parameters such as BMI, waist circumference, waist to hip ratio, and fat percentage (2,7). However, similar correlations have not been found in patients with early onset type 2 diabetes (8). While some reports related FGF21 with insulin sensitivity (3,9), other studies did not confirmed such association using hyperglycemic clamp (10). Although the current information supports the role of FGF21 as metabolic regulator inducing glucose uptake (3), and fatty acids oxidation (5,6), further research is necessary to clarify its function, regulation and clinical relevance in humans. Currently, a direct relationship between glucose and FGF21 has been reported (7,8). In addition, the serum FGF21 levels are higher in patients with metabolic syndrome than without it (4,7). Nowadays, the associated mechanism that explains this increment is not well understood.

**Justification of the study**

Recently, our group identified a significant association between BMI, fasting glucose, uric acid and physical activity with FGF21 (7). Associated with the higher of level of FGF21 in insulin resistance states (4,7,8), it could be suspected that circumstances with higher level of free fatty acids (FFAs) induce activity of PPAR-alpha in liver and the expression and synthesis of FGF21 is incremented. Sedentary lifestyle is frequently related with overweight, obesity, and metabolic syndrome. Usually, these abnormalities are related with higher serum level of FFAs. Therefore, we consider justify evaluating the effect of other clinical circumstances that induce lipolysis and increase FFAs level on serum FGF21. Using a better methodological clinical design, we propose a study to confirm the impact of physical activity on FGF21. Moreover, the measurement of FFAs could also allow us to identify the possible mechanism related.

**6a. Hypothesis**

Serum FGF21 levels will increase after a supervised intensive exercise program.

**6b. Study aims**

**a. Primary aim**

1. Evaluate the impact of two weeks of supervised intensive physical activity program on serum FGF21 levels, in a group of young sedentary healthy women.

**a. Secondary aims**

1. Evaluate the association between FGF21 with:
   a. Serum free fatty acids (FFAs) level,
   b. Metabolic equivalents (METs),
   c. Epinephrine,
   d. Glucose and insulin,
   e. Anthropometric parameters
   f. Leptin and total adiponectin

**7. Methodology**

*Study design*

Longitudinal, comparative, clinical intervention study to evaluate the possible change on serum FGF21 levels after a single bout and after two weeks of exercising.

*Description of intervention*

*Physical activity*

Selected women will be invited to a treadmill test following the Bruce’s protocol. The FGF21 level will be measured at the beginning (baseline), after 1 hour and 4 hours of the first test, and after two weeks of daily activity (final). We will study only women because the lipolytic response after exercising is higher in women than in men (11), and have lower cardiovascular risk with intensive physical activity. The treadmill test will be done every day during two weeks (except weekends). The schedule will be determined according the availability of the treadmill in the Department of Cardiology of this Institution.
Bruce’s protocol

The Bruce’s protocol is a multistage, well standardized test, including monitoring the cardiac function with electrocardiogram during exercise (12). The protocol has seven stages, each lasting three minutes, resulting in 21 minutes’ exercise for a complete test. In stage 1, patients walk at 1.7 mph (2.7 km) up a 10% incline. Energy expenditure is estimated to be 4.8 metabolic equivalents (METs) during this stage. The speed and inclination increased in each stage. From the second to the seventh stage, the speed increases from 2.5 mph (4.0 km/hr) to 6.0 mph (9.6 km/hr), and inclination from 12 to 22%. METs increases from 7.0 to 22.0, respectively. Assessment of workload is measured by metabolic equivalents (METs) which are an indirect reflection of oxygen consumption and energy use. One MET is 3.5 ml oxygen/kg per minute, which is the oxygen consumption of an average individual at rest. To carry out the activities of daily living exercise intensity of at least 5 METs is required (12). By convention, the maximum predicted heart rate is calculated as 220 (210 for women) minus the subject’s age. A satisfactory heart rate response is achieved on reaching 85% of the maximum predicted heart rate (12). Therefore, we will maintain the heart rate above the 85% at least 15 minutes in each test. In the following table the Bruce’s protocol is described:

<table>
<thead>
<tr>
<th>Phase</th>
<th>Speed (millas/hr)</th>
<th>Speed (km/hr)</th>
<th>Inclination (%)</th>
<th>METs</th>
<th>Time (minutes)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1.7</td>
<td>2.7</td>
<td>10</td>
<td>4.7</td>
<td>3</td>
</tr>
<tr>
<td>2</td>
<td>2.5</td>
<td>4.0</td>
<td>12</td>
<td>7.0</td>
<td>3</td>
</tr>
<tr>
<td>3</td>
<td>3.4</td>
<td>5.4</td>
<td>14</td>
<td>10.1</td>
<td>3</td>
</tr>
<tr>
<td>4</td>
<td>4.2</td>
<td>6.7</td>
<td>16</td>
<td>12.9</td>
<td>3</td>
</tr>
<tr>
<td>5</td>
<td>5.0</td>
<td>8.0</td>
<td>18</td>
<td>16.0</td>
<td>3</td>
</tr>
<tr>
<td>6</td>
<td>5.5</td>
<td>8.8</td>
<td>20</td>
<td>19.0</td>
<td>3</td>
</tr>
<tr>
<td>7</td>
<td>6.0</td>
<td>9.6</td>
<td>22</td>
<td>22.0</td>
<td>3</td>
</tr>
</tbody>
</table>

METs are used to quantify the intensity of physical activity in one person. The degree of physical activity can be classified in three levels:

- Low intensity: 1.1 - 2.9 METs
- Moderate intensity: 3.0 – 5.9 METs
- Vigorous intensity: 6.0 or more METs

The physical activity planned in the participants will be of vigorous intensity to induce a substantial adrenergic response, lipolytic effect and increment of FFAs in blood. However, the treadmill test will be stopped if any of the following circumstances is present:

a. Fatigue: when the participant ask to stop the test because of fatigue or muscle pain.

b. Maximum heart rate: the test will be stopped if the participant reach its maximum heart rate defined as 210-age.

Clinical evaluation

a) A complete clinical history and exploration will be developed in each participant to confirm inclusion and discard exclusion criteria (see below).

b) In addition, a standardized nutritionist will be measuring weight, height, waist and hip circumferences at the beginning and the end of the study. Fat percentage and free fat mass will also be measured using a UM-026 Tanita Body Composition Analyzer (Tanita, Tokyo).
Biochemical evaluation
The baseline and final samples will be taken after 8 to 12 hour fasting. The following parameters will be measured:

a) Glucose, insulin, uric acid, creatinine, total cholesterol, triglycerides, HDL-c, LDL-c, GGT, and liver tests.
b) FGF21, leptin and total adiponectin.
c) Free fatty acids.
d) Epinephrine

After the first hour and fourth hour of the first treadmill test, the following parameters will be measured:

a) Glucose and insulin
b) FGF21, leptin and adiponectin
c) Free fatty acids
d) Epinephrine

Serum samples will be preserved at -80° C until its analysis. Additionally, women that could be pregnant because of a menstrual period delay will be evaluated with serum beta subunit of human chorionic gonadotropin.

Sample size
Sample size for FGF21
We expected a minimum delta of 80 ng/L of FGF21 between the baseline and final evaluations. The SD of FGF21 in Mexican population with and without metabolic syndrome was of 160 ng/L (7). Considering an alpha of 0.05 (two sided) and beta of 0.20, with study power of 80%, we obtained a simple size of 63 subjects. The formula and calculations is described as follows:

N = \frac{2S^2 (Zα+Zβ)^2}{\Delta^2}
N = 2(160)^2 (1.96+0.84)^2 / 80^2
N = 96,800 (7.84) /80^2
N = 63 subjects (only one study group).

8. Methodology: Selection Criteria

Inclusion criteria
1. Women
2. Age between 18 to 35 years
3. Written informed consent signed.

Exclusion criteria
1. Individuals with the following circumstances will be excluded:
   a. Diabetes (any type), treatment with insulin or glucose lowering drugs (i.e., metformin).
   b. History of cardiovascular disease such as heart failure, ischemic heart disease or stroke.
   c. Liver failure or cirrhosis
   d. Kidney failure (acute or chronic)
   e. Peripheral vascular insufficiency.
   f. Chronic disease such as HIV, lupus, viral hepatitis, etc.
   g. Acute infection (i.e., flu, diarrhea).
2. Metabolic syndrome defined by ATP III Criteria (13).
3. Treatment for:
   a. Dyslipidemia (i.e, fibrates or statins)
   b. Asthma (i.e., beta agonists)
   c. Hypertension (i.e., beta blockers)
4. Contraindication for treadmill test (12):
   a. Ischemic heart disease
   b. Angina
   c. Heart failure
   d. Acute myocarditis or pericarditis
c. Acute systemic infection
f. Deep venous thrombosis
g. Uncontrolled hypertension (systolic >220 mmHg or diastolic > 120 mmHg)
h. Severe aortic stenosis
i. Hypertrophic cardiomyopathy
j. Arrhythmia
k. Aneurysm
l. Recent aortic surgery

Elimination Criteria
1. Confirmed pregnancy throughout study
2. Missed any treadmill test at second week
3. Physical injury during study

9. Methodology: Outcomes and variables

Variables and definitions

Treadmill test using Bruce’s protocol

Supervised physical activity will be developed following the Bruce’s protocol as described above (12). We will use the METs as ordinal variable to quantify the energy consumption throughout study.

Anthropometry

Anthropometric measurements will be done after participants removed their shoes and upper garments. Body weight and fat percentage will be quantified with the UM-026 Tanita Body Composition Analyzer (Tanita, Tokyo). All subjects will be instructed to stand in the centre of the scale during weight assessment. Height will be obtained using a floor scale’s stadiometre, again with the patient standing on the central part of the scale. Height will be measured to the nearest 0.5 cm. BMI will be calculated as weight (kg) divided by height (m²). Abdominal circumference will be measured to the nearest 0.1 cm at the level of the greatest frontal extension of the abdomen between the bottom of the rib cage and the top of the iliac crest. All measurements will be done after 8 to 12 hour of fasting.

During clinical evaluation a standarized nutritionist will measure:

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Measurement</th>
<th>Variable type</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight</td>
<td>kg.</td>
<td>Quantitative</td>
<td>Measurement in a daily calibrated scale.</td>
</tr>
<tr>
<td>Height</td>
<td>Meters</td>
<td>Quantitative</td>
<td>Measurement in a floor scale’s stadiometre for adults.</td>
</tr>
<tr>
<td>Blood pressure</td>
<td>mmHg</td>
<td>Quantitative</td>
<td>After resting 5 min. Every 2 minutes during treadmill test.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>continuous</td>
<td>Sphygmomanometer with mercury manometer and well sized cuff.</td>
</tr>
<tr>
<td>Waist</td>
<td>cm.</td>
<td>Quantitative</td>
<td>Measuring tape adjusted for millimeters (description above).</td>
</tr>
<tr>
<td>Hip</td>
<td>cm.</td>
<td>Quantitative</td>
<td>Measuring tape adjusted for millimeters (description above).</td>
</tr>
<tr>
<td>Fat percentage</td>
<td>%</td>
<td>Quantitative</td>
<td>Tanita analyzer (description above).</td>
</tr>
</tbody>
</table>

Using these parameters the following indexes will be calculated:

a) Body mass index (BMI):  Weight (kg) / Height²

b) Hip to waist ratio (WHR): Waist (cm.) / Height (cm.)

Biochemical evaluations

The laboratory of the Department of Endocrinology and Metabolism of the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ) will measure the biochemical parameters following standardized procedures. Commercial assays will be used. All subjects will be evaluated after 8 to 12 hours of fasting. Creatinine, uric acid, fasting glucose, lipid profile, liver tests and GGT will be measured using enzymatic assay by Beckman Coulter, Inc. Fasting insulin will be measured using a monoclonal assay (MEIA, Abbott Laboratories). All equipment is regularly calibrated using reference samples provided by the manufacturer. A human FGF21 ELISA kit will be used (BioVendor Laboratory Medicine, Modrice, Czech Republic) following the procedure described previously (7). This assay does not
have cross reaction with other human FGFs, adiponectin or leptin. Serum adiponectin and leptin (Millipore, Mexico), free fatty acids (Wako Chemicals, USA), and adrenaline (MP Biomedicals, USA) will be determined by sandwich ELISA kit.

**Frequency of measurements (clinical and biochemical)**

a) Baseline after 8 to 12 hour of fasting.

b) After first hour and forth hour of the first treadmill test.

c) Final measurement after two weeks of physical activity.

**Success and failure criteria**

We will consider success with the increment of serum FGF21 levels after a single bout and/or after two weeks of physical activity. In the same way, we will consider failure the absence of any change in the protein.

**Statistical analyses strategy**

Normally distributed data will be determined using Kolmogorov-Smirnov test and will be expressed as means and standard deviation (±SD), whereas variables with a skewed distribution will be reported as median (interquartile range) and log transformed to approximate normality before analyses. Chi Square, Student’s unpaired t test, Wilcoxon signed rank test or Mann-Whitney U test will be used as appropriate for comparison between groups. Homogeneity of variance will be evaluated with Levene’s test. Correlation coefficients between FGF21 and continuous variables will be evaluated in all participants, and will be calculated using the Spearman’s, Pearson’s r tests or using partial correlation analysis when adjusted for BMI. Kruskall-Wallis test or one-way ANOVA will be used for comparing continuous variables of patients stratified by tertiles of serum levels of FGF21. To evaluate the effect of exercise on clinical and biochemical parameters, we will use the difference between final – basal levels (or “delta”). We will calculate the mean of resting and maximum values and will be defined as the sum of values / number of tests. We will calculate the mean of resting and maximum heart rate, systolic and diastolic blood pressure as specified. Stepwise linear regression model will be used to examine the impact of variables in delta log serum FGF21 levels (model 1) and delta FFAs (model 2). The variables selected into the regression analyses will be those that correlate significantly with serum FGF21 or FFAs and those that have been associated with plasma levels of these proteins (4, 13). All reported p values will be based on two-sided tests considering ≤0.05 as significant. All analyses will be performed with SPSS (Chicago, IL).

**10. Risk and benefits of the study**

**Studies with risk**

Throughout this study, the risk of an adverse event during the simple test is practically absent. We will take around 20 ml of blood per participant for complete evaluation. The major risk is during the treadmill test. In every test, a continuous electrocardiographic monitoring will be undertaken, and every two minutes the blood pressure will be measure. In case of any abnormalities during the test, it will be suspended until clarify the reason. The participant will persist or be eliminated according to the cause of the abnormality. The treadmill test will be developed inside a Hospital; therefore, any evaluation could be done immediately with the space and the equipment necessary. An emergency room will be also available during the tests. If any injury is present, we will call the specific specialist for evaluation. The costs of the evaluation and treatment will be absorbed by the Department of Endocrinology. All these risks are considered minimum because of the population that will be studied.

**Expected benefits**

The participant will know her clinical and biochemical results without any cost. The result of treadmill test will also be proportioned. Any abnormality will be considered for future advising after the study ends.

**Risks vs. Benefits**

We consider that the benefits obtained with this study are over the risks described above.

**Procedure in case of injury**

The participants will have the clinical researchers mobile phone which is active 24/7. In case of any complain, the participant will be invited to go to the Institution for further evaluation. The evaluation will be held by the principal investigator itself to take the decisions accordingly.
Considerations for Research in Humans
All participants who accomplished the inclusion criteria will be informed of possible benefits and risks of the study. All the procedures that will be done throughout the study will be well described and authorized by the participant. If the evaluation carries out any diagnostic abnormality, the individual will be immediately informed and orientation regarding future studies or treatments will be proportioned without cost. All clinical investigation will be conducted according to the principles expressed in the Declaration of Helsinki.

11. Costs
The research will not generate substantial cost for study participants. All the costs of clinical and biochemical evaluations, including the treadmill test will be absorbed by the Department of Endocrinology and Metabolism of the INCNMSZ.

12. References

15c. Decision
<table>
<thead>
<tr>
<th>Aproved</th>
<th>X</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not aproved</td>
<td></td>
</tr>
<tr>
<td>Pending result</td>
<td></td>
</tr>
</tbody>
</table>